MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma
Pleura and Peritoneum · 26.06.2019 · 4 (2)
DOI: 10.1515/pp-2019-0010 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pleura and Peritoneum, online erschienen am 27.06.2019. Verfasst von Olivia Sgarbura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Surgical oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Malignant peritoneal mesothelioma (MPM) is a rare tumoral disease characterized by the diffuse involvement of the peritoneal serosa. The standard frontline treatment of MPM is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) unless the peritoneal disease is considered unresectable. For unresectable patients the standard frontline treatment is a combination of cisplatin and pemetrexed but the prognosis remains ominous with only 13 months of overall survival (OS).
Methods
The proposed study is a multicenter randomized non-comparative study evaluating the association of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy vs. systemic chemotherapy alone as first-line treatment of MPM. Patients will be randomized with a 2:1 ratio using a minimization technique. Sixty-six patients have to be enrolled. Stratification will be performed according to histology (epithelioid vs. sarcomatoid and biphasic), presence of extraperitoneal disease and center. Primary objective is OS and secondary objectives include progression-free survival (PFS), safety, compliance, feasibility, conversion to resectability, histological response to treatment and quality of life.
Conclusions
We expect to show that intensification of the first line treatment with PIPAC for initially unresectable MPM patients increases OS.
Trial registration
Prospective study. Clinicaltrials.gov: NCT03574493 EudraCT: 2019–001515-23.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surgical oncology Department, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
- Biometrics Unit, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
- Early phase clinical trial unit, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
- Surgery Department, Lyon Sud University Hospital, Claude Bernard University, Lyon, France.
- Clinical Research Department, Montpellier Cancer Institute (ICM), Univ. Montpellier, Montpellier, France.
- INSERM U1275, CAP Paris-Tech, Carcinomatosis Peritoneum Paris Technology, Lariboisière Hospital, AP-HP, 2 rue Ambroise Paré - 75010 Paris - Université de Paris, France.
ORCID-Profile: Olivia Sgarbura
Zitieren
APA
Sgarbura, O., Gourgou, S., Tosi, D., Bakrin, N., Bouazza, N., Delaine, S., De Forges, H., Pocard, M., & Quénet, F. (2019). MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura and Peritoneum, 4(2). https://doi.org/10.1515/pp-2019-0010
Vancouver
Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, et al. MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma. Pleura and Peritoneum. 2019;4(2). doi:10.1515/pp-2019-0010
BibTeX
@article{Sgarbura2019,
author = {Sgarbura, Olivia and Gourgou, Sophie and Tosi, Diego and Bakrin, Naoual and Bouazza, Nabila and Delaine, Stéphanie and De Forges, Hélène and Pocard, Marc and Quénet, François},
title = {MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma},
journal = {Pleura and Peritoneum},
year = {2019},
volume = {4},
number = {2},
doi = {10.1515/pp-2019-0010}
}
EUVIMED